Semaglutide formulation: what is in the licensed product besides the peptide

Semaglutide formulation: what is in the licensed product besides the peptide — setting out what I have, and where I think it stops being reliable.

I have spent a fortnight trying to pin semaglutide formulation down and I want to set out where I have got to, because I suspect the honest answer is duller than the thread this will produce.

What I have: a consistent observation across a small number of cases, collected the same way each time. What I do not have: any controlled comparison, or any reason to think my cases are representative.

The specific question is whether the pattern survives once the obvious confounder is removed. I cannot remove it with what I have.

The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.

Someone should write this up properly, and it should probably not be me.

Narrowing post #3, because the general version has more than one answer.

The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice. Visible particles or frank cloudiness is different and would be reason to contact the supplier.

I am reporting what happened, not recommending it.

Post #3 put the caveat in the right place and I want to underline it.

Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.

One case, stated as one case.

The mass figure differs between sources because of how the different entities report it. The monoisotopic mass of the bare peptide is one number; the mass including the acylation is another. Different sources emphasise different details.

That matches what I have seen, for whatever a single anecdote is worth.

Counter-ion form matters for the arithmetic and is almost never stated. A vial labelled 5 mg of peptide as an acetate salt and one labelled 5 mg as trifluoroacetate do not contain the same quantity of the molecule you are interested in.

I would want the raw data before agreeing with my own summary of it.

On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.

I have seen it go both ways, which is why I hedge.

Picking up post #8: that is the part I would want checked first.

Solutions of semaglutide can look faintly opalescent without anything being wrong. Visible particulate, fibres or frank cloudiness are a different observation entirely and are worth raising with the supplier rather than reasoning about.

The short answer was in the first line; everything after is the working.

Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.

I would want to see it done twice before believing it once.

On formulation: the licensed product is buffered and includes a preservative in the multi-dose presentation. A reconstituted research preparation matches neither, and stability claims made about the first do not carry over to the second.

Agreed on all of that, and I have nothing to add to it.

Post #10 describes the usual case. This is about the unusual one.

On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval is not arbitrary — it is what stops two doses stacking inside one absorption window.

The short version is the first sentence; the rest is why.